Skip to content
6-K

Foreign Interim / Material

CureVac N.V.

0001410578-25-001369

← back to feed
Filed
May 20, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2025 · Mar 31, 2025 225.15M sh
Shares Diluted restated Q1 2025 · Mar 31, 2024 224.35M sh
Operating Cash Flow Q1 2025 · Mar 31, 2025 −€41.37M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −€96.55M
Cash And Equivalents Q1 2025 · Mar 31, 2025 €438.33M
Cash And Equivalents Q1 2025 · Dec 31, 2024 €481.75M
Cash And Equivalents Q1 2025 · Mar 31, 2024 €300.15M
Cash And Equivalents Q1 2025 · Dec 31, 2023 €402.45M
Stockholders Equity Q1 2025 · Mar 31, 2025 €646.69M
Stockholders Equity Q1 2025 · Dec 31, 2024 €696.61M
Stockholders Equity Q1 2025 · Mar 31, 2024 €446.91M
Stockholders Equity Q1 2025 · Dec 31, 2023 €516.94M
Current Liabilities Q1 2025 · Mar 31, 2025 €61.29M
Current Liabilities Q1 2025 · Dec 31, 2024 €72.35M
Total Liabilities Q1 2025 · Mar 31, 2025 €95.58M
Total Liabilities Q1 2025 · Dec 31, 2024 €106.22M
Current Assets Q1 2025 · Mar 31, 2025 €469.1M
Current Assets Q1 2025 · Dec 31, 2024 €526.41M
Total Assets Q1 2025 · Mar 31, 2025 €742.27M
Total Assets Q1 2025 · Dec 31, 2024 €802.83M
Eps Diluted Q1 2025 · Mar 31, 2025 −€0.23
Eps Diluted Q1 2025 · Mar 31, 2024 −€0.31
Eps Basic Q1 2025 · Mar 31, 2025 −€0.23
Eps Basic Q1 2025 · Mar 31, 2024 −€0.31
Rd Expense Q1 2025 · Mar 31, 2025 €37.59M
Rd Expense Q1 2025 · Mar 31, 2024 €27.83M
Net Income Q1 2025 · Mar 31, 2025 −€52.08M
Net Income Q1 2025 · Mar 31, 2024 −€70.55M
Operating Income Q1 2025 · Mar 31, 2025 −€54.73M
Operating Income Q1 2025 · Mar 31, 2024 −€73.32M
Cost Of Revenue Q1 2025 · Mar 31, 2025 €875K
Cost Of Revenue Q1 2025 · Mar 31, 2024 €41.69M